About 343 results

ALLMedicine™ Cystinuria Center

Research & Reviews  101 results

Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA ad...
Expert Opinion on Drug Safety; Kumar V, Singh AP et. al.

Jul 15th, 2021 - D-penicillamine (D-pen) is a copper-chelating drug and has immune-modulatory properties. D-pen is used to treat rheumatoid arthritis, Wilson's disease, and kidney stones (cystinuria). However, associated adverse events (AEs) of D-pen treatment are...

Relationship between psychosocial characteristics and asthma management self-efficacy o...
Health Care for Women International; Yildirim B, Tuncay T

Jun 25th, 2021 - Primary tubulopathies are rare and usually present at pediatric age. Recent advances in genetic diagnosis and treatment have changed its natural history. This study provides the clinical spectrum of a series of primary tubulopathies diagnosed in a...

An Update on Evaluation and Management in Cystinuria.
Urology Daga S, Palit V et. al.

Jan 10th, 2021 - Cystinuria is the most common cause of inherited stone disease and is caused by the failure of absorption of filtered dibasic amino acids including cystine in the proximal tubules. It is associated with a very high recurrence rate in affected pati...

Clinical profile of a Polish cohort of children and young adults with cystinuria.
Renal Failure; Tkaczyk M, Gadomska-Prokop K et. al.

Dec 23rd, 2020 - Cystinuria is an inherited disorder that results in increased excretion of cystine in the urine. It accounts for about 1-2% of pediatric kidney stones. In this study, we sought to identify the clinical characteristics of patients with cystinuria i...

Non-contrast computed tomography characteristics in a large cohort of cystinuria patients.
World Journal of Urology; Warren H, Poon D et. al.

Nov 11th, 2020 - Cystine stones are widely considered hard and difficult to treat. Hounsfield Units (HU) are used in other stone types to estimate 'hardness' and treatments based on that finding. Our objective was to report mean HU of cystine stones in vivo in a l...

see more →

Drugs  20 results see all →

Clinicaltrials.gov  9 results

Effect of Increasing Doses of Tiopronin on Cystine Capacity in Patients With Cystinuria

Jan 13th, 2020 - The purpose of this study is to determine the minimum effective dose of the cysteine binding thiol drug (CBTD) Tiopronin on urine cystine capacity, which is a measure of cystine solubility in the urine, in patients with cystinuria to evaluate the ...

Rare Kidney Stone Consortium Patient Registry

Aug 19th, 2019 - This study involves the collection of medical information to create a computer database or registry for patients with PH, Dent disease, cystinuria and APRT deficiency. The information will be entered into the registry by your physician or health c...

TCUPS- Tolvaptan Use in Cyctinuria and Urolithiasis: A Pilot Study

Jan 23rd, 2019 - The goal of this research project is to establish that in short-term use, tolvaptan is a safe and potentially effective new therapy for cystinuria, by conducting a short-term pilot study of the safety and tolerability of this drug, and assess impa...

Prospective Research Rare Kidney Stones (ProRKS)

Oct 18th, 2018 - Severe, hereditary forms of nephrolithiasis cause marked excretion of insoluble minerals important in stone formation, including primary hyperoxaluria, cystinuria, Dent disease, and adenine phosphoribosyltransferase deficiency (APRTd). Patients wi...

Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria

Apr 5th, 2018 - Cystinuria is a rare genetic cause of kidney stones that leads to significant morbidity due to the recurrent nature of the disease. As a result, a significant part of treatment is focused on prevention of stone formation. Current methods of preven...

see more →

News  6 results

Diet vs Medications for Recurrent Kidney Stones

Jul 3rd, 2020 - The root causes of recurrent kidney stones can help physicians determine whether dietary changes or medication will be more helpful for at-risk patients, according to Glenn Preminger, MD, professor of urologic surgery at Duke University in Durham,...

FDA OKs New Formulation of Tiopronin for Cystinuria

Jul 2nd, 2019 - The US Food and Drug Administration (FDA) has approved an enteric-coated delayed-release formulation of tiopronin (Thiola EC, Retrophin) for treatment of cystinuria, a rare inherited disorder that causes an increase in cystine levels in the urine,...

Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure

What is the purpose of the Surrogate Endpoint Table? FDA’s surrogate endpoint table provides valuable information for drug developers on endpoints that may be considered and discussed with FDA for individual development programs. This table also f...

Paroxysmal Hemidyskinesia Related to a Large Thalamic Cyst

Feb 14th, 2007 - Introduction Symptomatic thalamic lesions are more frequently related to stroke, usually causing contralateral sensory symptoms, and less often to contralateral movement disorders. Thalamic lesions leading to movement disorders have been reported ...

Paroxysmal Hemidyskinesia Related to a Large Thalamic Cyst

Feb 14th, 2007 - Introduction Symptomatic thalamic lesions are more frequently related to stroke, usually causing contralateral sensory symptoms, and less often to contralateral movement disorders. Thalamic lesions leading to movement disorders have been reported ...

see more →

Patient Education  1 results see all →